Celcuity's High-Stakes Oncology Bet Is Underappreciated
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...
pharmaphorum1y
AZ first to AKT finish line, but FDA clears narrow label
The company’s head of oncology, Dave Fredrickson, said the approval of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test ...
Healio7d
VIDEO: PI3K inhibitors, combinations maintain quality-of-life in metastatic breast cancer
In this video, Aruna Padmanabhan, MD, discusses therapy combinations for the treatment of PIK3CA-mutated metastatic breast cancer.
mskcc.org8y
The Neal Rosen Lab: Research Overview
The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...